TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

This study is combining TACE (a procedure that delivers chemotherapy directly into liver tumors via a blood vessel) with an anti-PD-1 immunotherapy drug for people with advanced liver cancer (hepatocellular carcinoma) who have not yet received treatment. Researchers also want to study how the treatment changes the immune environment inside the tumor. **You may be eligible if...** - You are 18 or older - You have confirmed hepatocellular carcinoma at an advanced stage (or intermediate stage not suitable for curative treatment) - You have not received any prior cancer treatment (no chemotherapy, targeted therapy, immunotherapy, or TACE) - You have at least one measurable tumor - Your general health is good (ECOG 0–1) - Your liver, kidney, and blood counts are adequate **You may NOT be eligible if...** - You have received any prior systemic cancer treatment - You have an active autoimmune disease - You have an active infection requiring IV antibiotics - You are HIV-positive, or have active hepatitis B (with very high viral load) or hepatitis C - Your cancer has spread to the brain - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.